Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
ASCO GU Cancers Highlights
Nivolumab plus Cabozantinib Prolongs Survival in Advanced Renal-Cell Carcinoma
By
Patricia Stewart
ASCO GU Cancers Highlights
,
Renal-Cell Carcinoma
April 2021, Vol 11, No 4
The combination of nivolumab (Opdivo) plus cabozantinib (Cabometyx) continued to show superior survival outcomes compared with single-agent sunitinib (Sutent) as first-line treatment for patients with advanced renal-cell carcinoma (RCC), according to extended follow-up data from the phase 3 CheckMate-9ER clinical trial presented at the 2021 ASCO Genitourinary Cancers Symposium.
Read More ›
¹⁷⁷Lu-PSMA-617 Superior to Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
By
Patricia Stewart
ASCO GU Cancers Highlights
,
Prostate Cancer
April 2021, Vol 11, No 4
Cabazitaxel (Jevtana) is approved as third-line therapy for patients with metastatic castration-resistant prostate cancer (CRPC) after treatment with docetaxel and an androgen receptor inhibitor. A new phase 2 clinical trial shows that the radionuclide therapy that targets the prostate-specific membrane antigen (PSMA),
177
Lu-PSMA-617, reduced the risk for disease progression or death by 37% compared with cabazitaxel in men with previously treated metastatic CRPC. Moreover, the TheraP study showed that patients who received
177
Lu-PSMA-617 had fewer side effects and improved quality of life compared with patients who received cabazitaxel.
Read More ›
Enfortumab Vedotin Prolongs Survival in Patients with Metastatic Urothelial Cancer
By
Patricia Stewart
ASCO GU Cancers Highlights
,
Urothelial Cancer
April 2021, Vol 11, No 4
In patients with metastatic urothelial cancer who received previous therapy, as well as in cisplatin-ineligible patients with this cancer, enfortumab vedotin-ejfv (Padcev) improved overall survival (OS), according to new data presented at the 2021 ASCO Genitourinary Cancers Symposium. The data come from the phase 3 EV-301 study and cohort 2 of the phase 2 EV-201 study. Experts believe this antibody–drug conjugate will become a new standard of care in the treatment of patients with advanced urothelial cancer.
Read More ›
Ivosidenib Extends Survival in Patients with Cholangiocarcinoma and IDH1 Mutation
By
Wayne Kuznar
ASCO GU Cancers Highlights
,
Cholangiocarcinoma
April 2021, Vol 11, No 4
Final results from the phase 3 clinical trial ClarIDHy showed that ivosidenib (Tibsovo), a first-in-class oral inhibitor of isocitrate dehydrogenase 1 (
IDH1
) mutation, prolonged the median overall survival (OS) in patients with previously treated advanced cholangiocarcinoma (CCA) and
IDH1
mutation. Although this improvement did not reach statistical significance, after adjusting for crossovers from the placebo group to the ivosidenib group, the difference in median OS improvement was statistically significant.
Read More ›
Zanidatamab Demonstrates Durable Antitumor Activity in HER2-Overexpressing Gastric Cancers
By
William King
Gastrointestinal Cancers
,
ASCO GU Cancers Highlights
April 2021, Vol 11, No 4
The
HER2
-targeted bispecific investigational antibody zanidatamab, either as monotherapy or in combination with chemotherapy, has shown promising antitumor activity in an ongoing phase 1 clinical trial of patients with
HER2
-expressing biliary tract cancer or gastroesophageal adenocarcinoma, reported Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics, M.D. Anderson Cancer Center, Houston, TX, at the 2021 ASCO Gastrointestinal Cancers Symposium.
Read More ›
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Specialty Carve-Outs: What Are the Implications for Patients and Practices?
By
Dawn Holcombe, MBA, FACMPE, ACHE
2.
New Policies Regarding Intravenous Iron Replacement Are Creating Conundrum for Providers and Payers
By
Dawn Holcombe, MBA, FACMPE, ACHE
3.
2023 Spotlight: Amgen
Home
Issues
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes